Skip to main content
Premium Trial:

Request an Annual Quote

Pharma Spent $38.8B on R&D in 2004, a 12-Percent Jump; Breakdown on Genomic Spending Due Soon

NEW YORK, Feb. 18 (GenomeWeb News) - Member companies of the Pharmaceutical Research and Manufacturers of America collectively spent $38.8 billion on R&D last year in their drug-discovery and -development efforts, the organization said today.


The $38.8 billion in R&D represents a 12-percent increase over the $34.5 billion pharma collectively spent on R&D in 2003, and tops a steady increase in R&D over more thantwo decades, the organization said.  1980, PhRMA spent $2 billion on R&D.


A breakdown of the R&D spending by research categories, such as genomics and proteomics, is expected to be ready in a few weeks, a representative of PhRMA told GenomeWeb News. In terms of R&D spending by location, PhRMA member companies spent $30.6 billion, or 18 percent of domestic sales, on R&D within the United States, and an estimated $8.2 billion on R&D abroad.


PhRMA President and CEO Billy Tauzin said the US drug industry "is the world's largest source of investment in discovering better treatments [and exceeds] the international pharmaceutical industry and the National Institutes of Health."

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.